T2 Biosystems to Host Webinar on the Vital Role of Transformative Diagnostics in Optimizing Antimicrobial Stewardship

LEXINGTON, Mass., Jan. 25, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today that the company, in collaboration with LabRoots, will host a webinar on January 31, 2017 beginning at 10:00 a.m. PT/1:00 p.m. ET.

The webinar will examine the critical role of rapid diagnostics and antimicrobial stewardship in improving patient outcomes and reducing overall healthcare costs associated with sepsis. With sepsis claiming approximately 500,000 livesⁱ in the U.S. each year and costing healthcare systems more than $23.7 billion annually,ⁱⁱ healthcare systems are looking to provide more effective and efficient care to their patients while simultaneously reducing costs.

The most common sepsis-causing pathogens, bacteria and the fungal pathogen Candida, can lead to severe complications, and even death, if not diagnosed and treated rapidly. While these pathogens are currently detected by blood culture, which can take up to 6 days for results,ⁱⁱⁱ T2 Biosystems’ first sepsis pathogen diagnostic panel, the T2Candida^® Panel, generates results independent of blood culture in an average of 4.3 hours.^iv The T2Candida Panel may enable physicians to quickly initiate appropriate therapy or discontinue unnecessary antimicrobial therapy, effectively saving the lives of patients and delivering a strong economic return for healthcare institutions.

Dr. Michael A. Pfaller, will moderate the webinar and discuss how pairing a robust antimicrobial stewardship program with a rapid, highly sensitive, direct-from-blood diagnostic like the T2Candida Panel can fundamentally change clinical decisions in a way that saves and improves the lives of patients while delivering a strong economic return to healthcare institutions.

Dr. Pfaller will also discuss the preliminary details of the T2Bacteria™ Panel, which is anticipated to complete clinical trials and be submitted to the FDA by mid-2017.

LabRoots will host the webinar January 31, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. To read more on this event, learn about the continuing education credits offered, or to register for this free event, click here.

About Dr. Michael A. Pfaller

Dr. Pfaller earned his medical degree from the Washington University School of Medicine and currently serves as chief medical officer at T2 Biosystems, a role he’s held since 2014. He is a co-editor-in-chief of the 11^th edition of ASM Manual of Clinical Microbiology and co-author of Medical Microbiology, 7th Edition and has authored over 700 articles in peer-reviewed journals.

About T2 Biosystems

T2 Biosystems delivers diagnostic products that fundamentally change clinical decisions, in a way that saves and improves the lives of patients and delivers a strong economic return to healthcare institutions.  With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is a leader in the field of in vitro diagnostics.

The company leverages its proprietary T2 Magnetic Resonance platform, or T2MR^®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies.

In September 2014, the U.S. Food and Drug Administration authorized T2 Biosystems to market the T2Dx^® Instrument and T2Candida Panel. These are the first FDA-cleared products that enable species-specific detection of sepsis pathogens in an average of 4.3 hours without the need for blood culture, which typically takes 2 to 6 days. T2 Biosystems is currently developing their next three diagnostic applications – the T2Bacteria Panel and T2HemoStat Panel, which are focused on bacterial sepsis infections and hemostasis respectively, and the T2Lyme Panel to provide accurate and timely diagnosis of Lyme disease in partnership with Canon Life Sciences.

For more information, please visit www.t2biosystems.com.

About LabRoots

LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

ⁱ HCUP Statistical Brief #122. October 2011. Agency for Healthcare Research and Quality, Rockville, MD.

ⁱⁱ HCUP Statistical Brief #204. May 2016. Agency for Healthcare Research and Quality, Rockville, MD.

ⁱⁱⁱ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415728.htm. 

^iv Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 Magnetic Resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases. 2015;60.

Media Contact:
Susan Heins, Pure Communications
[email protected] 
864-346-8336

Investor Contact:
Matt Clawson, Pure Communications
[email protected] 
949-370-8500